We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
AAR Corp
AIR
$5.15B
| $20.6M | 0.09% |
456,552
-60,664
| -12% | -$2.63M |
|
252
ICU Medical
ICUI
$3.93B
| $20.5M | 0.09% |
109,689
-13,402
| -11% | -$2.31M |
|
253
Akamai
AKAM
$16.8B
| $20.4M | 0.09% |
236,655
+80,361
| +51% | +$7.03M |
|
254
Devon Energy
DVN
$51.9B
| $20.3M | 0.09% |
780,774
+762,740
| +4,229% | +$17.2M |
|
255
Hilton Worldwide
HLT
$74B
| $20.2M | 0.09% |
182,231
-511,202
| -74% | -$51.3M |
|
256
LCI Industries
LCII
$2.51B
| $20.2M | 0.09% |
188,605
-24,933
| -12% | -$2.52M |
|
257
Emerson Electric
EMR
$82.9B
| $19.6M | 0.09% |
257,630
-11,338
| -4% | -$817K |
|
|
MXIM
258
DELISTED
Maxim Integrated Products
MXIM
| $19.5M | 0.09% |
316,749
-18,498
| -6% | -$1.08M |
|
259
Boise Cascade
BCC
$2.74B
| $19.3M | 0.09% |
527,257
-69,655
| -12% | -$2.53M |
|
|
VCRA
260
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $19.1M | 0.09% |
921,227
-115,926
| -11% | -$2.54M |
|
261
AMN Healthcare
AMN
$1.28B
| $18.8M | 0.09% |
301,595
-154,395
| -34% | -$9.13M |
|
262
Lamar Advertising Co
LAMR
$16.2B
| $18.8M | 0.09% |
210,198
-8,333
| -4% | -$697K |
|
263
Jazz Pharmaceuticals
JAZZ
$15.9B
| $18.6M | 0.08% |
124,708
+101,015
| +426% | +$13.7M |
|
264
Supernus Pharmaceuticals
SUPN
$2.68B
| $18.5M | 0.08% |
782,079
-102,635
| -12% | -$2.49M |
|
265
LKQ Corp
LKQ
$6.58B
| $18.3M | 0.08% |
511,967
+395,238
| +339% | +$13.4M |
|
266
Gartner
IT
$9.41B
| $17.5M | 0.08% |
113,602
+531
| +0.5% | +$81.1K |
|
267
Vanguard Growth ETF
VUG
$216B
| $17.4M | 0.08% |
572,208
+18,030
| +3% | +$521K |
|
268
Delek US
DK
$3.87B
| $17.3M | 0.08% |
517,385
-56,024
| -10% | -$2.02M |
|
269
Lockheed Martin
LMT
$134B
| $17.3M | 0.08% |
44,427
+3,867
| +10% | +$1.48M |
|
270
Mercury Systems
MRCY
$6.2B
| $17.3M | 0.08% |
250,086
-31,149
| -11% | -$2.24M |
|
271
NETGEAR
NTGR
$669M
| $17.2M | 0.08% |
703,443
-92,098
| -12% | -$2.52M |
|
|
AVTA
272
DELISTED
Avantax, Inc. Common Stock
AVTA
| $17.1M | 0.08% |
652,838
-85,502
| -12% | -$1.91M |
|
273
Vanguard Small-Cap Value ETF
VBR
$37.1B
| $16.9M | 0.08% |
123,499
+5,462
| +5% | +$724K |
|
274
Granite Construction
GVA
$5.45B
| $16.8M | 0.08% |
607,651
-81,735
| -12% | -$2.32M |
|
275
Corteva
CTVA
$59.7B
| $16.7M | 0.08% |
566,274
-1,097,330
| -66% | -$29.1M |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.